全文获取类型
收费全文 | 21479篇 |
免费 | 1873篇 |
国内免费 | 864篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 461篇 |
妇产科学 | 465篇 |
基础医学 | 2357篇 |
口腔科学 | 176篇 |
临床医学 | 1642篇 |
内科学 | 3519篇 |
皮肤病学 | 140篇 |
神经病学 | 1841篇 |
特种医学 | 668篇 |
外科学 | 1696篇 |
综合类 | 2694篇 |
现状与发展 | 3篇 |
预防医学 | 1546篇 |
眼科学 | 158篇 |
药学 | 4366篇 |
7篇 | |
中国医学 | 1425篇 |
肿瘤学 | 1012篇 |
出版年
2024年 | 79篇 |
2023年 | 391篇 |
2022年 | 718篇 |
2021年 | 966篇 |
2020年 | 790篇 |
2019年 | 654篇 |
2018年 | 688篇 |
2017年 | 677篇 |
2016年 | 746篇 |
2015年 | 760篇 |
2014年 | 1112篇 |
2013年 | 1540篇 |
2012年 | 1104篇 |
2011年 | 1020篇 |
2010年 | 853篇 |
2009年 | 817篇 |
2008年 | 850篇 |
2007年 | 821篇 |
2006年 | 775篇 |
2005年 | 706篇 |
2004年 | 581篇 |
2003年 | 571篇 |
2002年 | 509篇 |
2001年 | 490篇 |
2000年 | 398篇 |
1999年 | 354篇 |
1998年 | 326篇 |
1997年 | 364篇 |
1996年 | 314篇 |
1995年 | 285篇 |
1994年 | 281篇 |
1993年 | 258篇 |
1992年 | 272篇 |
1991年 | 253篇 |
1990年 | 237篇 |
1989年 | 210篇 |
1988年 | 210篇 |
1987年 | 213篇 |
1986年 | 175篇 |
1985年 | 230篇 |
1984年 | 265篇 |
1983年 | 146篇 |
1982年 | 181篇 |
1981年 | 154篇 |
1980年 | 153篇 |
1979年 | 130篇 |
1978年 | 120篇 |
1977年 | 102篇 |
1976年 | 98篇 |
1975年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
81.
82.
F. M. Ulivieri L. P. Piodi G. Marotta D. Marchelli C. Commadini L. Parravicini C. Verdoia P. Gerundini 《Journal of orthopaedics and traumatology》2006,7(4):192-194
Osteoprotegerin (OPG) is a protein that inhibits of osteoclastogenesis. The aim this study was to evaluate the response of
serum OPG levels to neridronate treatment in patients with Paget's disease of bone resistant to previous therapy. Nine patients
(4 men) affected by active Paget’s disease of bone (6 polyostotic, 3 monostotic) not responsive to clodronate were studied.
Serum OPG, osteocalcin, total and bone isoenzyme of alkaline phosphatase (AP and BAP, respectively), and urinary deoxypyridinoline
(DPD) were measured before and 5 months after neridronate treatment (100 mg/day, i.v. for two days). A scintigraphic activity
index (SAI) was also calculated before treatment. Mean baseline OPG levels were within normal values and were not significantly
different 5 months after neridronate treatment. In contrast, there were significant reductions in AP (41.9%, p<0.02) and BAP (38.8%, p<0.04). Serum OPG levels correlated with DPD (r=0.925) and SAI (r=0.689). Although OPG is an important regulator of bone metabolism,
in our series of already treated patients it was not a sensitive marker for diagnosing Paget's disease and for monitoring
the response to pharmacological treatment, whereas AP and BAP confirmed their clinical usefulness. This preliminary study
requires confirmation by a study with a larger population. 相似文献
83.
目的:研究田径运动员最大摄氧量和Wingate测试后血乳酸的变化,分析血乳酸对测试结果的意义。方法:测试田径短跑运动员36例和中长跑运动员29例的最大摄氧量和Wingate无氧功,以及测试后的血乳酸值。结果:最大摄氧量测试后血乳酸数值为9~11mmol/L左右,摄氧量与乳酸值没有直接相关关系,但不同项目之间有一定的差异;Wingate测试后血乳酸数值一般大于12mmol/L,测试的主要评价指标与乳酸值都有较高的相关关系。结论:血乳酸值对于最大摄氧量测试意义不大,但对于Wingate测试可以作为一项辅助评价指标。 相似文献
84.
复方甲基炔诺酮片为含甲基炔诺酮(0.3mg/片)和炔雌醇(0.03mg/片)的糖衣片,对其有效成分含量的测定已有比色法、高效液相色谱法、导数分光光度法、荧光法及正交函数法。本文用三波长分光光度法消除组分间的相互干扰,对甲基炔诺酮和炔雌醇的含量进行测定,操作简便。 相似文献
85.
Using NADH fluorometry to monitor myocardial metabolism, the mechanism of reperfusion injury was investigated after the delivery of an experimental reperfusate. Using an isolated working heart preparation, rat hearts underwent 15 min of global ischemia at 37 degrees C. Following the ischemic insult, an oxygenated enriched reperfusion solution was given for 5 min. The hearts were then returned to a working state and aortic flow recorded to evaluate recovery. NADH levels were monitored throughout the experiment with a fluorometer and glycogen, AMP, ADP, and ATP were measured biochemically pre- and postischemia, after reperfusion and after recovery. In this study, reperfusion injury was best abated by an enriched reperfusate. Our results indicate the mechanism for this amelioration is not high-energy phosphate replenishment. Rather, as indicated by NADH fluorescence, the hearts attain an intermediate level of metabolism that permits glycogen to be restored and functional recovery to be improved. 相似文献
86.
Seven middle-aged men with manifest type II diabetes mellitus underwent an endurance training programme for 10–15 weeks. The maximal aerobic capacity, as well as the endurance capacity, was improved by 10% (p<0.05). The intramuscular glycogen store increased by more than 80% (p<0.05) from 350 μmol/g dw (dry weight), and the activities of citrate synthase and 3-hydroxy-acyl-CoA dehydrogenase increased by more than 50% (p<0.05) and 30% (p<0.05). The activity of glycogen synthase was decreased by approximately 20% (p<0.05), whereas lactate dehydrogenase remained unchanged. Capillaries/fibre and fibre area increased by more than 50% (p<0.05) and 30% (p<0.05) leaving the area of supply constant. Training did not influence fasting blood lipids and glucose, glycosylated hemoglobin, oral glucose tolerance, and insulin response to an oral glucose load measured 72 hours post-exercise. It is concluded that patients with manifest type II diabetes, as normoglycaemic individuals, adapt to physical training. However, no persistent effect on glucohomeostasis and lipaemia is produced by short-term training in the diabetic patients. 相似文献
87.
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS AND KININ METABOLISM: EVIDENCE THAT ACE INHIBITORS MAY INHIBIT A KININASE OTHER THAN ACE 总被引:1,自引:0,他引:1
Duncan J. Campbell 《Clinical and experimental pharmacology & physiology》1995,22(12):903-911
1. Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, and also metabolizes bradykinin-(1–9) to bradykinin-(1–7) and bradykinin-(1–7) to bradykinin-(1–5). Increases in endogenous kinin levels may contribute to the therapeutic effects of ACE inhibitors. 2. ACE inhibitors increase vascular levels of both bradykinin-(1–9) and its ACE cleavage product bradykinin-(1–7), at doses below the threshold for ACE inhibition, leading to the proposal that ACE inhibitors may also inhibit a non-ACE kininase which cleaves both kinin peptides; this non-ACE kininase may be the major pathway of kinin metabolism in the vasculature and some other tissues. 3. In support of this proposal, ACE inhibitors potentiate bradykinin-(1–9) effects at doses which have little or no effect on ACE activity, as indicated by angiotensin I conversion to angiotensin II. ACE inhibitors also potentiate the actions of ACE-resistant kinin analogues, which may be susceptible to metabolism by a non-ACE kininase. 4. Identification and characterization of the putative non-ACE kininase which is inhibited by ACE inhibitors may reveal novel approaches to the tissue-specific modulation of kinin levels. 相似文献
88.
G.-M. Robertz-Vaupel K. D. Lindecken T. Edeki C. Funke S. Belwon H. J. Dengler 《European journal of clinical pharmacology》1992,42(5):465-469
Summary In the present study the effect of metastatic liver disease on hepatic drug metabolism has been examined by studying the pharmacokinetics of antipyrine and the urinary excretion of antipyrine and its three major metabolites (4-hydroxyantipyrine, norantipyrine, and 3-hydroxymethylantipyrine) in 12 patients with extensive metastatic liver disease, and in 12 matched healthy controls.In the patients total liver volume, the volume of the liver parenchyma, and the volume of the liver metastases were determined by computed tomography. The volume of liver metastases always exceeded 35% of the total liver volume.There were no significant differences between the patients and controls in plasma half-life, plasma clearance, or apparent volume of distribution of antipyrine.The cumulative urinary excretion of antipyrine and its three major metabolites was significantly lower in patients [44 (18)%] than in controls [71 (8)%]. The excretion of antipyrine itself was unchanged and the decrease in cumulative excretion was due to reduced excretion of the three metabolites.The results show that the activity of the hepatic mixed function oxidases was not impaired even in patients with extensive metastatic liver disease. This may be because liver metastases do not cause a corresponding reduction in the volume of normal hepatic parenchyma. The decreased urinary excretion of the three major metabolites of antipyrine, which are mainly glucuronidated, may have been due to an alteration in the process of conjugation. 相似文献
89.
乳腺癌组织中Cyclin D1及p16蛋白表达的联合检测及其意义 总被引:3,自引:1,他引:2
目的:探讨乳腺癌中Cyclin D1及p16蛋白表达的相关性及其临床意义。方法:LSAB法检测多种乳腺组织中Cyclin D1及p16蛋白的表达情况,结合有关临床资料,分析Cyclin D1和p16蛋白表达异常与乳腺癌中重要的临床病理因素的关系。结果:62例乳腺癌组织中,Cyclin D1蛋白过度表达占48·4%,其表达与乳腺癌组织学分级呈明显正相关,且Cyclin D1蛋白过度表达更常见于ER、PR阳性的乳腺癌中。乳腺癌旁组织中Cyclin D1蛋白过度表达为20·0%,其他几种乳腺组织很少有CyclinD1蛋白的过度表达。p16蛋白仅在58·1%的乳腺癌组织中有表达,且p16的表达与组织学分级程度有负相关关系。正常乳腺组织中未见p16蛋白的异常。结论:乳腺癌组织中存在着Cyclin D1蛋白的过度表达及p16蛋白的异常,二者对乳腺癌组织的增殖分化有一定的影响。 相似文献
90.